|
![]() |
|
|
Heparin
drug data and news
Heparin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Heparin | ||
| Brand Names/Synonyms | 000 Units in Sodium Chloride 0.45%; 000 Units in Sodium Chloride 0.9%; Alpha-Heparin; Ariven; Arteven; Bemiparin; CY 216; Calcilean; Calciparine; Certoparin; Clexane; Clivarin; Clivarine; Cy 222; Dalteparin; Depo-Heparin; Enoxaparin; Enoxaparin Sodium; Eparina [Dcit]; FR 860; Fluxum; Fragmin A; Fragmin B; Fraxiparin; HSDB 3094; Hed-Heparin; Hepalean; Heparin; Heparin Cy 216; Heparin Leo; Heparin Lock Flush; Heparin Sodium; Heparin Sodium Preservative Free; Heparin Sodium Salt; Heparin Sulfate; Heparinate; Heparinic Acid; Hepathrom; KB 101; Leparan; Lipo-Hepin; Liquaemin; Liquaemin Sodium; Liquemin; Low Molecular Weight Heparin Sodium; Multiparin; Novoheparin; OP 386; OP 622; Pabyrin; Parnaparin; Parvoparin; Pularin; Reviparin; Sandoparin; Sodium Heparin; Sublingula; Thromboliquine; Vetren; Vitrum Ab | ||
| Indication | For Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension, for prevention of post-operative deep venous thrombosis and pulmonary embolism , Prevention of clotting in arterial and cardiac surgery. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Heparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Heparin is a well known and commonly used anticoagulant which has antithrombotic properties. Heparin is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin. Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Heparin acts at multiple sites in the normal coagulation system. Small amounts of Heparin in combination with antithrombin III (Heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of Heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. | ||
| Mechanism Of Action | The mechanism of action of Heparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of Heparin is well correlated to the inhibition of factor Xa. Heparin interacts with Antithrombin III, Prothrombin and Factor X. | ||
| Heparin News (When available) |
Cut risks of killer blood clots 07 Mar 2006 PolyMedix Appoints Edward Smith Vice President Finance and CFO 07 Mar 2006 The Pulse of Heart-Drug Research Mar 5, 2006 Acquired haemophilia in urticarial vasculitis revealed by ... Feb 28, 2006 Low-Molecular-Weight Heparin More Effective in Ischemic Stroke ... Feb 22, 2006 Vegan? Sorry, We Have Porcine Heparin on the Menu! Feb 21, 2006 Alternative method to produce heparin Feb 7, 2006 Synthetic Heparin may replace current drug Feb 6, 2006 New way to produce Heparin discovered through RPI collaboration Feb 7, 2006 What ‘They’ Don’t Want You to Know Mar 3, 2006 Patient Safety Authority Marks Patient Safety Awareness Week March ... Mar 4, 2006 HOW DID OUR DAD DIE? Mar 3, 2006 The Doctor's World Sharon, Gravely Ill, Invited the Public Inside Feb 27, 2006 (PRN) Encysive Pharmaceuticals Announces Retirement of Frank C. ... Mar 3, 2006 Medical Edge: Brace may help osteoporosis patient Mar 4, 2006 Researcher looks for more targeted way to deliver cancer drugs Feb 21, 2006 Liquidating a lethal blood clot Feb 6, 2006 RPI aids blood-clot prevention Feb 7, 2006 New Oral Anticoagulants Show Promise Feb 14, 2006 PolyMedix Raises $21 Million in Equity Financing; Company Will ... Feb 22, 2006 change it from life-threatening to Feb 26, 2006 Complete occlusion of the left main coronary artery complicated by ... Feb 28, 2006 Defending Human Embryonic Life - Essay Feb 27, 2006 Nuvelo Reports 2005 Fourth Quarter and Year End Results and ... Feb 27, 2006 Emisphere Technologies Announces Presentation and Webcast at the ... Mar 1, 2006 Biotie Therapies Oyj: Biotie therapies corp. revised outlook for ... Mar 1, 2006 Cutting angioplasty risks Feb 16, 2006 'Pharmed' goats seek drug licence Feb 22, 2006 CardioTech International Reports Results for Third Quarter of ... Feb 14, 2006 PolyMedix raises $21.2M, completes merger Feb 22, 2006 Arixtra Administered the Morning After Orthopedic Surgery ... Feb 3, 2006 Searching for Memory: The Brain, the Mind, and the Past Feb 7, 2006 Parker & Waichman, LLP Files Suit Against Ortho-McNeil ... Feb 24, 2006 Pivotal Study Published in British Medical Journal Reports ... Feb 13, 2006 Encysive Pharmaceuticals Reports Fourth Quarter and Year End 2005 ... Feb 13, 2006 Angioplasty Treatment Can Vary Feb 11, 2006 Arixtra Effective and Well Tolerated in Acutely Ill Medical ... Feb 14, 2006 Angioplasty Needs Guidance Feb 14, 2006 Blood clots in legs can be examined, prevented Feb 9, 2006 Activation of the coagulation system during coronary artery bypass ... Feb 9, 2006 Thrombolytic Treatment Before Stenting Linked to Increased ... Feb 14, 2006 Superior vena cava replacement for lung cancer using a ... Feb 14, 2006 Biotechs? Use rubber gloves Feb 3, 2006 International Teleradiology Feb 15, 2006 Plasmin Modulates Vascular Endothelial Growth Factor-A-Mediated ... Feb 8, 2006 Patient care for Muslims a new need Feb 16, 2006 New Clinical Data Points to Promising Treatment for Ischemic ... Feb 16, 2006 | ||
| Dosage Forms | Solution for subcutaneous injection, intravenous injection, or intravenous infusion | ||
| Drug_Category | Fibrinolytic Agents; Anticoagulants; Heparins; ATC:B01AB01; ATC:C05BA01; ATC:C05BA03; ATC:S01XA09; ATC:S01XA14 | ||
| Absorption | Some oral absorption but lack of anticoagulant effect. Rapidly taken up by endothelial cells with remainder bound to plasma proteins. | ||
| Interactions |
-->Interactions for Heparin: Drug Interactions:
Drug/ Laboratory Tests Interactions Hyperaminotransferasemia: Significant elevations of aminotransferase (SGOT [S-AST] and SGPT [S-ALT]) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin sodium. Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease and pulmonary emboli, rises that might be caused by drugs (heparin sodium) should be interpreted with caution. | ||
| Toxicity | Heparin sodium - Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 6-[5-acetylamino-4,6-dihydroxy-2-(sulfooxymethyl)tetrahydropyran-3-yl]oxy-3-[5-(6-carboxy-4,5-dihydroxy-3-sulfooxy-tetrahydropyran-2-yl)oxy-6-(hydroxymethyl)-3-sulfoamino-4-sulfooxy-tetrahydropyran-2-yl]oxy-4-hydroxy-5-sulfooxy-tetrahydropyran-2-carboxylicacid | ||
| Chemical Formula | (C26H40N2O36S5)n | ||
| Molecular Weight | 12000-15000 g/mol | ||
| Smiles String | CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O | ||
| Melting Point | Not Available | ||
| Water Solubility | Soluble | ||
| State | Solid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Liver and the reticulo-endothelial system are the sites of biotransformation. | ||
| Half Life | 1.5 hours | ||
| Protein Binding [%] | Very high, mostly to low-density lipoproteins | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Heparin.html http://www.rxlist.com/cgi/generic/heparin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00056 | ||
| CAS Registry Number | 9005-49-6 | ||
| KEGG Compound ID | C00374 | ||
| PubChem ID | SID:2789 | ||
| PharmGKB ID | PA449855 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 453781 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |